Your top strategic priority is managing the cost of patient care.
Yet you are at the center of a changing healthcare environment.
Dwindling reimbursements have become your
number one financial challenge.
Costs to treat hospital-acquired pressure injuries are approaching $11 billion annually. It's a non-reimbursable condition that can cost between $500 and $70,000 per individual injury—a substantial financial burden on organizations.
Bottom line: preventing a pressure injury is less costly than treating it.
DermaTherapy® was engineered to prevent pressure injuries and promote healing. It is FDA cleared* to help reduce the likelihood of patients developing pressure ulcers by reducing moisture, friction and shear on the patient's skin.
According to a clinical trial evaluating DermaTherapy® technology published in the November 2017 issue of the American Journal of Critical Care, authors of the study concluded: “The use of specialty linens in addition to standard techniques for preventing pressure injuries can help prevent pressure injuries from developing in high-risk patients in intensive care units.” (American Journal of Critical Care. 2017; 26: 474-481)
The article states that “cost savings more than covered the increased cost of the specialty linens.”
Innovative solutions are sometimes seen as drivers of increased healthcare costs if they fail to deliver positive outcomes.
DermaTherapy® therapeutic linen is an FDA cleared, evidence-based** solution that is proven to deliver positive outcomes.
The bed linens and patient gowns that touch a patient’s skin are often seen as housekeeping items, despite our individual healthcare needs. While billions of dollars are spent attempting to prevent pressure injuries, little attention has been given to the impact bedding and gowns may have on outcomes.
DermaTherapy® is the first and only therapeutic linen system to be granted U.S. Patents. (US 7,816,288 and US 8,283,267)
DermaTherapy® is a strategic supply chain solution that improves outcomes.
DermaTherapy® is also FDA cleared*** for use in the treatment of atopic dermatitis by patients who are susceptible to or may have mild atopic dermatitis, the most common form of eczema.
Your organization has worked hard to develop a record of excellence. You're well regarded for delivering quality care and clinical innovation.
Building a better healing environment is top of mind.
By changing how you confront the prevention of pressure ulcers, you maintain your edge in providing innovative, quality care.